OTCMKTS:SPHS

Sophiris Bio Competitors

$0.03
+0.01 (+64.10 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.02
Now: $0.03
$0.03
50-Day Range
$0.02
MA: $0.03
$0.04
52-Week Range
$0.00
Now: $0.03
$0.30
Volume136,741 shs
Average Volume388,506 shs
Market Capitalization$910,080.00
P/E RatioN/A
Dividend YieldN/A
Beta1.86

Competitors

Sophiris Bio (OTCMKTS:SPHS) Vs. AKRXQ, VGLS, ABMC, INNVD, IMNPQ, and RSPI

Should you be buying SPHS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Sophiris Bio, including Akorn (AKRXQ), VG Life Sciences (VGLS), American Bio Medica (ABMC), Innovus Pharmaceuticals (INNVD), Immune Pharmaceuticals (IMNPQ), and RespireRx Pharmaceuticals (RSPI).

Akorn (OTCMKTS:AKRXQ) and Sophiris Bio (OTCMKTS:SPHS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Akorn and Sophiris Bio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akorn$682.43 million0.01$-226,770,000.00N/AN/A
Sophiris BioN/AN/A$-6,780,000.00N/AN/A

Sophiris Bio has lower revenue, but higher earnings than Akorn.

Risk and Volatility

Akorn has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Sophiris Bio has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.

Insider and Institutional Ownership

0.1% of Akorn shares are owned by institutional investors. 3.9% of Akorn shares are owned by company insiders. Comparatively, 4.5% of Sophiris Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Akorn and Sophiris Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akorn-54.01%-5.13%-0.49%
Sophiris BioN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Akorn and Sophiris Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akorn0000N/A
Sophiris Bio0000N/A

Summary

Sophiris Bio beats Akorn on 6 of the 8 factors compared between the two stocks.

Sophiris Bio (OTCMKTS:SPHS) and VG Life Sciences (OTCMKTS:VGLS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Sophiris Bio and VG Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sophiris BioN/AN/AN/A
VG Life SciencesN/AN/AN/A

Valuation and Earnings

This table compares Sophiris Bio and VG Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sophiris BioN/AN/A$-6,780,000.00N/AN/A
VG Life SciencesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sophiris Bio and VG Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sophiris Bio0000N/A
VG Life Sciences0000N/A

Risk & Volatility

Sophiris Bio has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Summary

Sophiris Bio beats VG Life Sciences on 1 of the 1 factors compared between the two stocks.

Sophiris Bio (OTCMKTS:SPHS) and American Bio Medica (OTCMKTS:ABMC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Sophiris Bio and American Bio Medica's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sophiris BioN/AN/AN/A
American Bio Medica-18.99%N/A-35.34%

Valuation and Earnings

This table compares Sophiris Bio and American Bio Medica's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sophiris BioN/AN/A$-6,780,000.00N/AN/A
American Bio Medica$3.65 million0.96$-680,000.00N/AN/A

American Bio Medica has higher revenue and earnings than Sophiris Bio.

Risk & Volatility

Sophiris Bio has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, American Bio Medica has a beta of -1.45, meaning that its share price is 245% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sophiris Bio and American Bio Medica, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sophiris Bio0000N/A
American Bio Medica0000N/A

Summary

Sophiris Bio beats American Bio Medica on 3 of the 5 factors compared between the two stocks.

Sophiris Bio (OTCMKTS:SPHS) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.

Profitability

This table compares Sophiris Bio and Innovus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sophiris BioN/AN/AN/A
Innovus Pharmaceuticals-34.51%-682.54%-78.57%

Valuation & Earnings

This table compares Sophiris Bio and Innovus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sophiris BioN/AN/A$-6,780,000.00N/AN/A
Innovus Pharmaceuticals$23.99 million0.00$-8,280,000.00($4.16)N/A

Sophiris Bio has higher earnings, but lower revenue than Innovus Pharmaceuticals.

Insider and Institutional Ownership

10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. 4.5% of Sophiris Bio shares are owned by company insiders. Comparatively, 16.4% of Innovus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Sophiris Bio has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Sophiris Bio and Innovus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sophiris Bio0000N/A
Innovus Pharmaceuticals0000N/A

Immune Pharmaceuticals (OTCMKTS:IMNPQ) and Sophiris Bio (OTCMKTS:SPHS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Profitability

This table compares Immune Pharmaceuticals and Sophiris Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Immune PharmaceuticalsN/AN/AN/A
Sophiris BioN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for Immune Pharmaceuticals and Sophiris Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immune Pharmaceuticals0000N/A
Sophiris Bio0000N/A

Risk and Volatility

Immune Pharmaceuticals has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Sophiris Bio has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.

Valuation and Earnings

This table compares Immune Pharmaceuticals and Sophiris Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immune PharmaceuticalsN/AN/AN/AN/AN/A
Sophiris BioN/AN/A$-6,780,000.00N/AN/A

Summary

Sophiris Bio beats Immune Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

RespireRx Pharmaceuticals (OTCMKTS:RSPI) and Sophiris Bio (OTCMKTS:SPHS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Valuation and Earnings

This table compares RespireRx Pharmaceuticals and Sophiris Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RespireRx PharmaceuticalsN/AN/A$-2,120,000.00N/AN/A
Sophiris BioN/AN/A$-6,780,000.00N/AN/A

Profitability

This table compares RespireRx Pharmaceuticals and Sophiris Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RespireRx PharmaceuticalsN/AN/A-3,387.16%
Sophiris BioN/AN/AN/A

Risk and Volatility

RespireRx Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Sophiris Bio has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for RespireRx Pharmaceuticals and Sophiris Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RespireRx Pharmaceuticals0000N/A
Sophiris Bio0000N/A

Summary

Sophiris Bio beats RespireRx Pharmaceuticals on 2 of the 3 factors compared between the two stocks.


Sophiris Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AKRXQ
Akorn
0.1$0.03+0.0%$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01+0.0%$3.50 millionN/A0.00Gap Up
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.09+0.0%$3.50 million$3.65 million0.00News Coverage
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14+7.3%$2.88 millionN/A0.00Gap Up
RespireRx Pharmaceuticals logo
RSPI
RespireRx Pharmaceuticals
0.5$0.04+0.0%$2.82 millionN/A-0.09
VVUSQ
VIVUS
0.6$0.12+0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48+6.2%$2.02 millionN/A0.00
NSPX
Inspyr Therapeutics
0.5$0.01+0.0%$1.97 millionN/A0.00Gap Down
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01+0.0%$1.95 million$2 million0.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04+0.0%$1.78 million$530,000.000.00Gap Up
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.48+6.2%$1.70 millionN/A0.00
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.01+0.0%$1.65 million$20,000.00-0.74Gap Down
Cardax logo
CDXI
Cardax
0.0$2.00+0.0%$1.59 million$710,000.000.00News Coverage
MLNTQ
Melinta Therapeutics
0.2$0.11+0.0%$1.51 million$96.43 million0.00
WWHC
W World
0.8$4.50+35.3%$1.33 millionN/A0.00Increase in Short Interest
Gap Up
Achaogen logo
AKAOQ
Achaogen
0.6$0.03+0.0%$1.29 million$8.73 million0.00Gap Up
HSTC
HST Global
0.8$0.24+67.9%$1.24 millionN/A0.00
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.22+9.3%$1.14 millionN/A0.00Decrease in Short Interest
News Coverage
Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05+0.0%$1.12 millionN/A-0.57Upcoming Earnings
AOXG
Aoxing Pharmaceutical
0.5$0.01+0.0%$991,000.00N/A0.00Gap Up
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04+0.0%$978,000.00N/A0.00Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07+0.0%$970,000.00N/A0.00Increase in Short Interest
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01+0.0%$958,000.00N/A0.00Increase in Short Interest
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08+0.0%$872,000.00$250,000.000.00
PXYN
Praxsyn
0.6$0.00+0.0%$848,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05+0.0%$572,000.00$1.90 million0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02+0.0%$547,000.00N/A0.00Gap Up
TRPXD
Therapix Biosciences
0.0$9.25+2.7%$462,000.00N/A0.00High Trading Volume
Gap Up
BSPM
Biostar Pharmaceuticals
0.0$0.15+46.4%$399,000.00N/A0.00News Coverage
SKVI
Skinvisible
0.7$0.08+83.3%$376,000.00$40,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01+0.0%$343,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47+3.7%$338,000.00$36.55 million0.00Gap Up
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01+0.0%$244,000.00N/A0.00
WDBG
Woodbrook Group
0.0$1.60+0.0%$224,000.00N/A0.00
PZRXQ
PhaseRx
0.2$0.02+0.0%$185,000.00N/A0.00Gap Up
ROSGQ
Rosetta Genomics
0.0$0.08+24.2%$151,000.00N/A0.00Gap Down
OREXQ
Orexigen Therapeutics
0.4$0.01+26.4%$100,000.00$33.71 million0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.01+69.0%$82,000.00$20,000.000.00
AXMP
AXM Pharma
0.2$0.00+0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00+0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00+0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.01+0.0%$7,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.04+22.7%$0.00N/A0.00
Affymax logo
AFFY
Affymax
0.6$0.08+12.5%$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50+0.0%$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01+0.0%$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.01+0.0%$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07+0.0%$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01+0.0%$0.00N/A0.00
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.